Ivenix Appoints New Head With $42m Cash Infusion
This article was originally published in Clinica
Executive Summary
Ivenix, a company developing a next-generation infusion pump system, has appointed Stuart Randle CEO. The appointment comes a few months after the Amesbury, Massachusetts firm bagged a $42m financing round, led by new investor, China-based WuXi Healthcare Ventures. Prior to joining Ivenix, Randle was president and CEO of another Massachusetts firm, GI Dynamics, which was focused on type 2 diabetes and obesity. The infusion system market is not new to Ivenix’s new head: he began his career at Baxter where he spent 10 years in various senior sales and marketing roles.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.